Next-generation sequencing of advanced prostate cancer treated with androgen-deprivation therapy
Background Androgen-deprivation therapy (ADT) is standard treatment for locally advanced or metastatic prostate cancer (PCa). Many patients develop castration resistance (castration-resistant PCa [CRPC]) after approximately 2-3 yr, with a poor prognosis. The molecular mechanisms underlying CRPC prog...
| 主要な著者: | , , , , , , , , , , , , , , |
|---|---|
| フォーマット: | Journal article |
| 言語: | English |
| 出版事項: |
Elsevier
2014
|
| _version_ | 1826297241998983168 |
|---|---|
| author | Rajan, P Sudbery, I Villasevil, M Mui, E Fleming, J Davis, M Ahmad, I Edwards, J Sansom, O Sims, D Ponting, C Heger, A McMenemin, R Pedley, I Leung, H |
| author_facet | Rajan, P Sudbery, I Villasevil, M Mui, E Fleming, J Davis, M Ahmad, I Edwards, J Sansom, O Sims, D Ponting, C Heger, A McMenemin, R Pedley, I Leung, H |
| author_sort | Rajan, P |
| collection | OXFORD |
| description | Background Androgen-deprivation therapy (ADT) is standard treatment for locally advanced or metastatic prostate cancer (PCa). Many patients develop castration resistance (castration-resistant PCa [CRPC]) after approximately 2-3 yr, with a poor prognosis. The molecular mechanisms underlying CRPC progression are unclear. Objective To undertake quantitative tumour transcriptome profiling prior to and following ADT to identify functionally important androgen-regulated pathways or genes that may be reactivated in CRPC. Design, setting, and participants RNA sequencing (RNA-seq) was performed on tumour-rich, targeted prostatic biopsies from seven patients with locally advanced or metastatic PCa before and approximately 22 wk after ADT initiation. Differentially regulated genes were identified in treatment pairs and further investigated by quantitative reverse transcription-polymerase chain reaction (qRT-PCR) on cell lines and immunohistochemistry on a separate CRPC patient cohort. Functional assays were used to determine the effect of pathway modulation on cell phenotypes. Outcome measurements and statistical analysis We searched for gene expression changes affecting key cell signalling pathways that may be targeted as proof of principle in a CRPC in vitro cell line model. Results and limitations We identified ADT-regulated signalling pathways, including the Wnt/β-catenin signalling pathway, and observed overexpression of β-catenin in a subset of CRPC by immunohistochemistry. We validated 6 of 12 (50%) pathway members by qRT-PCR on LNCaP/LNCaP-AI cell RNAs, of which 4 (67%) demonstrated expression changes consistent with RNA-seq data. We show that the tankyrase inhibitor XAV939 (which promotes β-catenin degradation) reduced androgen-independent LNCaP-AI cell line growth compared with androgen-responsive LNCaP cells via an accumulation of cell proportions in the G0/G1 phase and reduction in the S and G2/M phases. Our biopsy protocol did not account for tumour heterogeneity, and pathway inhibition was limited to pharmacologic approaches. Conclusions RNA-seq of paired PCa samples revealed ADT-regulated signalling pathways. Proof-of-principle inhibition of the Wnt/β-catenin signalling pathway specifically delays androgen-independent PCa cell cycle progression and proliferation and warrants further investigation as a potential target for therapy for CRPC. © 2013 European Association of Urology. |
| first_indexed | 2024-03-07T04:28:35Z |
| format | Journal article |
| id | oxford-uuid:cd841afc-2a5e-4c4f-8ec6-fca0a7d53cb9 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T04:28:35Z |
| publishDate | 2014 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | oxford-uuid:cd841afc-2a5e-4c4f-8ec6-fca0a7d53cb92022-03-27T07:29:22ZNext-generation sequencing of advanced prostate cancer treated with androgen-deprivation therapyJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:cd841afc-2a5e-4c4f-8ec6-fca0a7d53cb9EnglishSymplectic Elements at OxfordElsevier2014Rajan, PSudbery, IVillasevil, MMui, EFleming, JDavis, MAhmad, IEdwards, JSansom, OSims, DPonting, CHeger, AMcMenemin, RPedley, ILeung, HBackground Androgen-deprivation therapy (ADT) is standard treatment for locally advanced or metastatic prostate cancer (PCa). Many patients develop castration resistance (castration-resistant PCa [CRPC]) after approximately 2-3 yr, with a poor prognosis. The molecular mechanisms underlying CRPC progression are unclear. Objective To undertake quantitative tumour transcriptome profiling prior to and following ADT to identify functionally important androgen-regulated pathways or genes that may be reactivated in CRPC. Design, setting, and participants RNA sequencing (RNA-seq) was performed on tumour-rich, targeted prostatic biopsies from seven patients with locally advanced or metastatic PCa before and approximately 22 wk after ADT initiation. Differentially regulated genes were identified in treatment pairs and further investigated by quantitative reverse transcription-polymerase chain reaction (qRT-PCR) on cell lines and immunohistochemistry on a separate CRPC patient cohort. Functional assays were used to determine the effect of pathway modulation on cell phenotypes. Outcome measurements and statistical analysis We searched for gene expression changes affecting key cell signalling pathways that may be targeted as proof of principle in a CRPC in vitro cell line model. Results and limitations We identified ADT-regulated signalling pathways, including the Wnt/β-catenin signalling pathway, and observed overexpression of β-catenin in a subset of CRPC by immunohistochemistry. We validated 6 of 12 (50%) pathway members by qRT-PCR on LNCaP/LNCaP-AI cell RNAs, of which 4 (67%) demonstrated expression changes consistent with RNA-seq data. We show that the tankyrase inhibitor XAV939 (which promotes β-catenin degradation) reduced androgen-independent LNCaP-AI cell line growth compared with androgen-responsive LNCaP cells via an accumulation of cell proportions in the G0/G1 phase and reduction in the S and G2/M phases. Our biopsy protocol did not account for tumour heterogeneity, and pathway inhibition was limited to pharmacologic approaches. Conclusions RNA-seq of paired PCa samples revealed ADT-regulated signalling pathways. Proof-of-principle inhibition of the Wnt/β-catenin signalling pathway specifically delays androgen-independent PCa cell cycle progression and proliferation and warrants further investigation as a potential target for therapy for CRPC. © 2013 European Association of Urology. |
| spellingShingle | Rajan, P Sudbery, I Villasevil, M Mui, E Fleming, J Davis, M Ahmad, I Edwards, J Sansom, O Sims, D Ponting, C Heger, A McMenemin, R Pedley, I Leung, H Next-generation sequencing of advanced prostate cancer treated with androgen-deprivation therapy |
| title | Next-generation sequencing of advanced prostate cancer treated with androgen-deprivation therapy |
| title_full | Next-generation sequencing of advanced prostate cancer treated with androgen-deprivation therapy |
| title_fullStr | Next-generation sequencing of advanced prostate cancer treated with androgen-deprivation therapy |
| title_full_unstemmed | Next-generation sequencing of advanced prostate cancer treated with androgen-deprivation therapy |
| title_short | Next-generation sequencing of advanced prostate cancer treated with androgen-deprivation therapy |
| title_sort | next generation sequencing of advanced prostate cancer treated with androgen deprivation therapy |
| work_keys_str_mv | AT rajanp nextgenerationsequencingofadvancedprostatecancertreatedwithandrogendeprivationtherapy AT sudberyi nextgenerationsequencingofadvancedprostatecancertreatedwithandrogendeprivationtherapy AT villasevilm nextgenerationsequencingofadvancedprostatecancertreatedwithandrogendeprivationtherapy AT muie nextgenerationsequencingofadvancedprostatecancertreatedwithandrogendeprivationtherapy AT flemingj nextgenerationsequencingofadvancedprostatecancertreatedwithandrogendeprivationtherapy AT davism nextgenerationsequencingofadvancedprostatecancertreatedwithandrogendeprivationtherapy AT ahmadi nextgenerationsequencingofadvancedprostatecancertreatedwithandrogendeprivationtherapy AT edwardsj nextgenerationsequencingofadvancedprostatecancertreatedwithandrogendeprivationtherapy AT sansomo nextgenerationsequencingofadvancedprostatecancertreatedwithandrogendeprivationtherapy AT simsd nextgenerationsequencingofadvancedprostatecancertreatedwithandrogendeprivationtherapy AT pontingc nextgenerationsequencingofadvancedprostatecancertreatedwithandrogendeprivationtherapy AT hegera nextgenerationsequencingofadvancedprostatecancertreatedwithandrogendeprivationtherapy AT mcmeneminr nextgenerationsequencingofadvancedprostatecancertreatedwithandrogendeprivationtherapy AT pedleyi nextgenerationsequencingofadvancedprostatecancertreatedwithandrogendeprivationtherapy AT leungh nextgenerationsequencingofadvancedprostatecancertreatedwithandrogendeprivationtherapy |